ArticleInternational journal of health policy and management2020
Meeting the Challenge of Diabetes in China.
Article in International journal of health policy and management, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Trial
- Observational
- Article
- Association of Type 2 Diabetes and Body Mass Index with Arterial Stiffness: A Carotid Ultrasound Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Confronting the economic burden of diabetes: Can TCM DRG payment reform in China offer a viable solution? Insights from empirical research in Western China.Frontiers in public health · 2026Article
- Evaluation of the diagnostic efficacy of different glycemic markers and insulin indices for diabetes mellitus in a general population.Annals of medicine · 2025Article
- Optimal obesity and lipid-related predictors of diabetes mellitus in middle-aged and elderly patients with liver disease in China: a CHARLS cross-sectional study.Diabetology international · 2025Article
- The effect of the urban built environment on the prevalence rate of chronic diseases in the community neighborhood level: a case study in Qingdao, China.BMC public health · 2025Article
- Resveratrol ameliorates early retinal neurodegeneration in diabetic retinopathy via microRNA-29b/specificity protein 1/apoptosis pathway by enhancing autophagy.European journal of nutrition · 2025Article
- Changes in pre-diabetes and diabetes prevalence and diabetes self-management behaviors across socioeconomic spectra in rural southwest China: 2013-2022.BMC public health · 2025Article
- Treatment Patterns and Glycaemic Control Between 2015 and 2019 in Tianjin, China: A Real-World Study of Adults with Type 2 Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Trends in liver cancer burden in China and G20: a comparative analysis using GBD 2021.Frontiers in oncology · 2025Article
- Exploring the impact of self-efficacy on glycemic control in Omani type 2 diabetes patients.Frontiers in endocrinology · 2025Article
- The association between resting heart rate and HbA1c-assessed glycemic control in patients with type 2 diabetes in Eastern China.Frontiers in endocrinology · 2025Article
- Factors influencing health-related quality of life among people with uncontrolled type II diabetes mellitus in Wenzhou, China: A cross-sectional study.Belitung nursing journal · 2025Article
- AI-Driven Management of Type 2 Diabetes in China: Opportunities and Challenges.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- A novel predictive model for optimizing diabetes screening in older adults.Journal of diabetes investigation · 2024Article
- Poricoic acid a ameliorates high glucose-induced podocyte injury by regulating the AMPKα/FUNDC1 pathway.Molecular biology reports · 2024Article
- Optimal obesity- and lipid-related indices for predicting type 2 diabetes in middle-aged and elderly Chinese.Scientific reports · 2024Article
- Research hotspots and trends in diabetes and insulin resistance: a bibliometric analysis.Frontiers in nutrition · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
China's estimated 114 million people with diabetes pose a massive challenge for China's health policy-makers who have significantly extended health insurance coverage over the past decade. What China is doing now, what it has achieved, and what remains to be done should be of interest to health policy-makers, worldwide. We identify the challenges posed by China's two principal strategies to tackle diabetes: (1) A short-term pilot strategy of health promotion, detection and control of chronic diseases in 265 national demonstration areas (NDAs); and (2) A long-term strategy to extend health promotion and strengthen primary care capacity and health system integration throughout China. Finally, we consider how Chinese innovations in artificial intelligence (AI) and Big Data may contribute to improving diagnosis, controlling complications and increasing access to care. Health system integration in China will require overcoming the fragmentation of a system that still places excessive reliance on local government financing. Moreover, what remains to be done resembles deeper challenges faced by healthcare systems worldwide: the need to upgrade primary care and reduce inequalities in access to health services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.